Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study

Aaron S. Kelly, Andrea M. Metzig, Kyle D. Rudser, Angela K. Fitch, Claudia K. Fox, Brandon M. Nathan, Mary M. Deering, Betsy L. Schwartz, M. Jennifer Abuzzahab, Laura M. Gandrud, Antoinette Moran, Charles J. Billington, Sarah J. Schwarzenberg

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity. Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI < 1.2 times the 95th percentile or BMI < 35 kg/m 2) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a drug phase of lifestyle modification plus exenatide. Participants were equally randomized to phase-order (i.e., starting with control or drug therapy) then crossed-over to the other treatment. BMI, body fat percentage, blood pressure, lipids, oral glucose tolerance tests (OGTT), adipokines, plasma biomarkers of endothelial activation, and endothelial function were assessed at baseline, 3-, and 6-months. The mean change over each 3-month phase was compared between treatments. Compared to control, exenatide significantly reduced BMI (< 1.7 kg/m 2, 95% confidence interval (CI) (3.0, 0.4), P = 0.01), body weight (3.9 kg, 95% CI (7.11, 0.69), P = 0.02), and fasting insulin (7.5 mU/l, 95% CI (13.71, 1.37), P = 0.02). Significant improvements were observed for OGTT-derived insulin sensitivity (P = 0.02) and Β-cell function (P = 0.03). Compliance with the injection regimen was excellent (94%) and exenatide was generally well-tolerated (the most common adverse event was mild nausea in 36%). These preliminary data suggest that exenatide should be evaluated in larger, well-controlled trials for its ability to reduce BMI and improve cardiometabolic risk factors in youth with extreme obesity.

Original languageEnglish (US)
Pages (from-to)364-370
Number of pages7
JournalObesity
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Pediatric Obesity
Weight Loss
Obesity
Confidence Intervals
Glucose Tolerance Test
Life Style
Therapeutics
Adipokines
Aptitude
Cross-Over Studies
Nausea
Insulin Resistance
Adipose Tissue
Fasting
Biomarkers
Body Weight
exenatide
Clinical Trials
Insulin
Blood Pressure

Cite this

Exenatide as a weight-loss therapy in extreme pediatric obesity : A randomized, controlled pilot study. / Kelly, Aaron S.; Metzig, Andrea M.; Rudser, Kyle D.; Fitch, Angela K.; Fox, Claudia K.; Nathan, Brandon M.; M. Deering, Mary; Schwartz, Betsy L.; Abuzzahab, M. Jennifer; Gandrud, Laura M.; Moran, Antoinette; Billington, Charles J.; Schwarzenberg, Sarah J.

In: Obesity, Vol. 20, No. 2, 01.02.2012, p. 364-370.

Research output: Contribution to journalArticle

Kelly, Aaron S. ; Metzig, Andrea M. ; Rudser, Kyle D. ; Fitch, Angela K. ; Fox, Claudia K. ; Nathan, Brandon M. ; M. Deering, Mary ; Schwartz, Betsy L. ; Abuzzahab, M. Jennifer ; Gandrud, Laura M. ; Moran, Antoinette ; Billington, Charles J. ; Schwarzenberg, Sarah J. / Exenatide as a weight-loss therapy in extreme pediatric obesity : A randomized, controlled pilot study. In: Obesity. 2012 ; Vol. 20, No. 2. pp. 364-370.
@article{ce446f27865f4461a28160ce9de0a6f3,
title = "Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study",
abstract = "The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity. Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI < 1.2 times the 95th percentile or BMI < 35 kg/m 2) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a drug phase of lifestyle modification plus exenatide. Participants were equally randomized to phase-order (i.e., starting with control or drug therapy) then crossed-over to the other treatment. BMI, body fat percentage, blood pressure, lipids, oral glucose tolerance tests (OGTT), adipokines, plasma biomarkers of endothelial activation, and endothelial function were assessed at baseline, 3-, and 6-months. The mean change over each 3-month phase was compared between treatments. Compared to control, exenatide significantly reduced BMI (< 1.7 kg/m 2, 95{\%} confidence interval (CI) (3.0, 0.4), P = 0.01), body weight (3.9 kg, 95{\%} CI (7.11, 0.69), P = 0.02), and fasting insulin (7.5 mU/l, 95{\%} CI (13.71, 1.37), P = 0.02). Significant improvements were observed for OGTT-derived insulin sensitivity (P = 0.02) and Β-cell function (P = 0.03). Compliance with the injection regimen was excellent (94{\%}) and exenatide was generally well-tolerated (the most common adverse event was mild nausea in 36{\%}). These preliminary data suggest that exenatide should be evaluated in larger, well-controlled trials for its ability to reduce BMI and improve cardiometabolic risk factors in youth with extreme obesity.",
author = "Kelly, {Aaron S.} and Metzig, {Andrea M.} and Rudser, {Kyle D.} and Fitch, {Angela K.} and Fox, {Claudia K.} and Nathan, {Brandon M.} and {M. Deering}, Mary and Schwartz, {Betsy L.} and Abuzzahab, {M. Jennifer} and Gandrud, {Laura M.} and Antoinette Moran and Billington, {Charles J.} and Schwarzenberg, {Sarah J.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1038/oby.2011.337",
language = "English (US)",
volume = "20",
pages = "364--370",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Exenatide as a weight-loss therapy in extreme pediatric obesity

T2 - A randomized, controlled pilot study

AU - Kelly, Aaron S.

AU - Metzig, Andrea M.

AU - Rudser, Kyle D.

AU - Fitch, Angela K.

AU - Fox, Claudia K.

AU - Nathan, Brandon M.

AU - M. Deering, Mary

AU - Schwartz, Betsy L.

AU - Abuzzahab, M. Jennifer

AU - Gandrud, Laura M.

AU - Moran, Antoinette

AU - Billington, Charles J.

AU - Schwarzenberg, Sarah J.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity. Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI < 1.2 times the 95th percentile or BMI < 35 kg/m 2) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a drug phase of lifestyle modification plus exenatide. Participants were equally randomized to phase-order (i.e., starting with control or drug therapy) then crossed-over to the other treatment. BMI, body fat percentage, blood pressure, lipids, oral glucose tolerance tests (OGTT), adipokines, plasma biomarkers of endothelial activation, and endothelial function were assessed at baseline, 3-, and 6-months. The mean change over each 3-month phase was compared between treatments. Compared to control, exenatide significantly reduced BMI (< 1.7 kg/m 2, 95% confidence interval (CI) (3.0, 0.4), P = 0.01), body weight (3.9 kg, 95% CI (7.11, 0.69), P = 0.02), and fasting insulin (7.5 mU/l, 95% CI (13.71, 1.37), P = 0.02). Significant improvements were observed for OGTT-derived insulin sensitivity (P = 0.02) and Β-cell function (P = 0.03). Compliance with the injection regimen was excellent (94%) and exenatide was generally well-tolerated (the most common adverse event was mild nausea in 36%). These preliminary data suggest that exenatide should be evaluated in larger, well-controlled trials for its ability to reduce BMI and improve cardiometabolic risk factors in youth with extreme obesity.

AB - The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity. Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI < 1.2 times the 95th percentile or BMI < 35 kg/m 2) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a drug phase of lifestyle modification plus exenatide. Participants were equally randomized to phase-order (i.e., starting with control or drug therapy) then crossed-over to the other treatment. BMI, body fat percentage, blood pressure, lipids, oral glucose tolerance tests (OGTT), adipokines, plasma biomarkers of endothelial activation, and endothelial function were assessed at baseline, 3-, and 6-months. The mean change over each 3-month phase was compared between treatments. Compared to control, exenatide significantly reduced BMI (< 1.7 kg/m 2, 95% confidence interval (CI) (3.0, 0.4), P = 0.01), body weight (3.9 kg, 95% CI (7.11, 0.69), P = 0.02), and fasting insulin (7.5 mU/l, 95% CI (13.71, 1.37), P = 0.02). Significant improvements were observed for OGTT-derived insulin sensitivity (P = 0.02) and Β-cell function (P = 0.03). Compliance with the injection regimen was excellent (94%) and exenatide was generally well-tolerated (the most common adverse event was mild nausea in 36%). These preliminary data suggest that exenatide should be evaluated in larger, well-controlled trials for its ability to reduce BMI and improve cardiometabolic risk factors in youth with extreme obesity.

UR - http://www.scopus.com/inward/record.url?scp=84856242456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856242456&partnerID=8YFLogxK

U2 - 10.1038/oby.2011.337

DO - 10.1038/oby.2011.337

M3 - Article

C2 - 22076596

AN - SCOPUS:84856242456

VL - 20

SP - 364

EP - 370

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 2

ER -